H.C. Wainwright upgraded Oric Pharmaceuticals to Buy from Neutral with a $16 price target. The analyst sees "significant potential" for ORIC-114, a CNS-penetrant EGFR/HER2 exon 20 inhibitor. The firm upgraded the shares after including ORIC-114 in its valuation assessment. It sees several data catalysts later this year for Oric.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ORIC:
- Oric Pharmaceuticals upgraded to Buy from Neutral at Guggenheim
- Oric Pharmaceuticals reports Q4 EPS (52c), consensus (55c)
- ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates
- Oric Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
- ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting
